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Ion iz ing  par ti cles  have  been  used  for  the  treat ment  of  ath ero scle ro sis.  In ter nal  ir ra di a tion  is
com  monly car  ried out by means of sev  eral meth  ods (cath  e  ter-based sys  tems, ra  dio  ac  tive
stents or bal  loons) to re  duce the prob  a  bil  ity of restenosis. 90Y, due to some of its char  ac  ter  is  -
tics, is an ap  pro  pri  ate ra  dio  iso  tope for intravascular brachytherapy. How  ever, since there are
some crit  i  cal tis  sues in the vi  cin  ity of the heart like the breast and lymph nodes, it is nec  es  sary
to  per form  a  do sim e try  cal cu la tion  around  the  ar tery  un der  ra dio ther apy  to  jus tify  the  treat -
ment method.  In this study, a 3-D dose dis tri bu tion was ob tained for the cor o nary ves sel and
its sur  round  ing tis  sues for a stan  dard 90Y stent in a MCNPX pro  gram. The re  sults were com  -
pared with other in  ves ti ga tions on restenosis pre ven tion us ing 90Y-coated stents. The cal  cu la  -
tions rep re sented a 28-day cu mu la tive dose be tween 1230 cGy and 2400 cGy at 0.1 mm from
the stent sur face, while this quan tity was about 23.8 cGy at 8.5 mm from the stent sur face. An
as sess ment of the dose equiv a lent and ef fec tive dose was also per formed at r = 8.5 mm for the
men  tioned sur  round  ing tis  sues which may be lo  cated in the area, based on the lat  est changes
in ICRP rec om men da tions.  Ad di tion ally, the dose equiv a lent cal cu lated within  the treat ment
pe  riod for these or  gans was com  pared with pub  lished do  sim  e  try data for 90Sr/90Y seed
sources  in  or der  to  eval u ate  ra di a tion  pro tec tion  con cerns  about  these  two  ra dio ther apy
meth  ods. It has been found that, de  pend  ing on stent pa  ram  e  ters, 90Y  stent  im plan ta tion
might in crease the un fa vor able side ef fects for the pa tient, but to a much lesser de gree than the 
other methods.
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IN TRO DUC TION
Ev  ery year hun  dreds of peo  ple die from ath  ero  -
scle  ro  sis. The dis  ease in  volves a nar  row  ing of the ar  -
ter  ies due to the ac  cu  mu  la  tion of fats and plaques
within the ar  tery walls, even  tu  ally lead  ing to a full
block  age of the ves  sel and a heart ar  rest. This oc  curs
par tic  u  larly in small and nar  row ves  sels. The re  oc  cur -
rence of the ste no sis af ter an angioplasty pro ce dure is a 
com  mon event ef  fect  ing an av  er  age of 30%-50% of
the pa  tients [1].
Ion  iz  ing ra  di  a  tion has been widely used for the
con  trol of proliferative tis  sues in tu  mors and has
proven to be suc  cess  ful [2]. There  fore, the use of ra  -
dio  ac  tive sources to pre  vent or re  duce restenosis
seems a ra  tio  nal ap  proach, as it has been ex  am  ined
over two de  cades. Sev  eral meth  ods have been tried,
in  clud  ing intravascular brachytherapy (IVBT) and in  -
sert ing  ra dio ac tive  stents.
IVBT  in cludes  cath e ter-based  sys tems,  usu ally
dur  ing or af  ter an angioplasty, to send a gamma or
beta- emit ting source such as a wire, a train of seeds, or
liq uid- or gas-filled bal loons into the ves sel in or der to
ir ra di ate the in jury area. On the other hand, ra dio ac tive 
stents are also used dur  ing the angioplasty pro  ce  dure
to re  duce restenosis. The two meth  ods dif  fer in some
as  pects, such as the dose rate, treat  ment pe  riod and
uni  for  mity of the dose around the de  vice and onto the
neointima.
Ra dio ac tive  stents  have  cer tain  ad van tages  over
cath e ter-based  sys tems.  Stent  im plan ta tion  is  per -
formed by means of a well-known pro  ce  dure of
angioplasty and is fa mil iar to car di ol o gists and easy to
ap  ply. The ac  tiv  ity of the stent can be as low as pos  si  -
ble be  cause the stent is very close to the neointima.
Also, stents are per  ma  nent im  plants, not sub  ject to a
need for rou tine pro ce dures such as con cerns about the 
re  moval and stor  age of the source and safety mat  ters
[3]. How  ever, the pro  ce  dure has some lim  i  ta  tions, in  -
clud ing the loss of the ad e quate dose to the tis sues near 
the stent mar  gins af  ter they have been in  jured by
angioplasty. The re  sult of this is the so-called
“candy-wrap per” ef fect which causes restenosis in the
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[4]. An  other prob  lem is that due to a high dose de  liv  -
ered near the sur  face of the stent, we'll have a de  layed
re  cov  ery in that area.
90Sr/90Y  has  some  in ter est ing  spec i fi ca tions  that
mo ti vate  its  ap pli ca tion  in  ra dio ther apy.  It  has  a  much
shorter half-life than a com  mon ra  dio  ther  apy
radionuclide such as 192Ir. Also, high-en  ergy neg  a  tive
beta par ti cles of  90Y are more pen e trat ing while hav ing 
a sharper slope of the depth dose.  Be  cause of these
fea tures and, due to the high-pu rity de cay of betas, 90Y
seems a more suit  able radionuclide for an ef  fec  tive
treat ment.  Fur ther more,  when  us ing  ra dio ac tive
sources, one of the most im  por  tant con  cerns in treat  -
ment plan ning is safety. Al though there is no dose limit 
for pa tients un der go ing ra dio ther apy prac tices, it is the 
phy si cian's  and  phys i cist's  re spon si bil ity  to  de liver  an
ad  e  quate dose to the tar  get while avoid  ing the nor  mal
tis  sues. Re  gard  ing the po  si  tion of the heart in the vi  -
cin  ity of some crit  i  cal tis  sues like the breast or lymph
nodes, it seems so im  por  tant to de  ter  mine an ac  cu  -
rately pre  scribed dose around the car  diac tis  sues be  -
fore mak ing a de ci sion about the treat ment pro ce dure.
Do sim e try  cal cu la tions  for  intravascular
brachytherapy with 90Sr/90Y seed sources have been
per formed through some ex per i men tal works and var -
i ous  sim u la tion  pro grams  [1,  2,  5-8].
Arabi et al. con ducted a do sim e try of re nal ar ter -
ies with a 48V stent [9]. Fischell et al. made a re view of
dif fer ent meth ods and sources for ap pli ca tion in ra dio -
ther apy  of  cor o nary  ar ter ies  [10].  Prestwich  et al. ob  -
tained a dose dis  tri  bu  tion pro  duced by a 32P-coated
stent [11].  McLemore et al. cal  cu lated the dose dis tri  -
bu tion  around  103Pd stents for IVBT [12].
A lim ited num ber of stud ies have been re  lated to
the  do sim e try  of  90Y-im  planted stents. Patel et al. cal  -
cu lated  dosimetric pa ram e ters for  a  90Y-coil source by
a Monte Carlo method [13]. Carter et al.  in ves ti gated
the ef  fects of cu  mu  la  tive dose and dose rate de  liv  ery
on neointimal for  ma  tion us  ing 32P and 90Y stents in a
por cine model of restenosis, both in an ex per i ment and 
in a com puter-based mod el  ing pro  gram [14]. They fo -
cused on the morphometry of the ves  sel af  ter the
place  ment of the ra  dio  ac  tive stent. Tay  lor et al.
worked on dose re  sponse char  ac  ter  is  tics of a 90Y stent
in a ca  nine cor  o  nary model [15]. As men  tioned, there
has been no im plicit and pre cise do sim e try cal cu la tion
of  a  car dio vas cu lar  sys tem  for  90Y stents, while con  -
sid  er  ing the prob  a  bil  ity of risks involed for sur  round  -
ing or  gans.
In this re search, dose rates and cu mu la tive doses
were cal  cu  lated us  ing a Monte Carlo method for a 90Y
stent im  planted into an ar  tery for 28 days. This pe  riod
was cho  sen due to the half-life of 90Y af  ter which we
will have a rel a tively full de cay of the ra dio iso tope. To
val i date  our  cal cu la tions,  the  re sult ing  sim u la tion  was
com  pared with other re  searches. Upon this, cal  cu  la  -
tions were done for the dose equiv  a lent within this pe -
riod, so as to pro  vide an eval  u  a  tion of the level of the
ef  fec  tive dose for nor  mal tis  sues which may be sit  u  -
ated nearby. The re  sults of these cal  cu  la  tions were as  -
sessed in com  par  i  son to the do  sim  e  try of a train of
90Sr/90Y seed sources in cardiovacular brachytherapy
in or der to clear some as pects of  the ra di a tion safety of
the pro  ce  dures, based on the ICRP103 re  port [16].
MA TE RI ALS  AND  METH ODS
90Y is a pure neg  a  tive beta-emit  ting source. Its
half-life is about 64 hours. 90Y has an av  er  age and
max  i  mum en  ergy of 935 keV and 2.28 MeV, re  spec  -
tively.  Its  par ent,  90Sr,  has  a  max i mum  en ergy of 546 
keV and a long half-life of 28.8 years. Since 90Y has a
short half-life and high en ergy, it de liv ers a high ini tial
dose to the tis  sue and this makes it an ap  pro pri ate can  -
di  date for treat  ment pur  poses.
90Y en  ergy spec  trum is a com  pli  cated one and
has been ob  tained through cal  cu  la  tions pre  sented in
[17]. Fig  ure 1 shows the cal  cu  lated en  ergy spec  trum
for 90Y.
 The stent had a meshed cy lin  dri cal shape with a
length of 15 mm and a di am e ter of 3 mm. The strut was
0.075 mm thick. The stent was com posed of a stain less
steel SS316L which con  sisted of Fe, Cr, Ni, Mn, Si,
Mo, P, S, and C, with a den sity of 8 g/cm3. The ac tiv ity
of the stent was con  sid  ered as 1.48×105 Bq.
The  car dio vas cu lar  phan tom  and  sur round ing
tis  sues were as  sumed as a sim  ple cyl  in  der of wa  ter
with a den  sity of 1 g/cm3.  A  cy lin dri cal  co-or di nate
sys  tem was used to mesh the cor  o  nary ves  sel and car  -
diac phan tom and cal cu late the dose rate at each voxel.
The or  i  gin of the co-or  di  nate sys  tem was matched to
the cen  ter of the stent. With an az  i  muthal sym  me  try,
cir  cu  lar voxels were made as 0.1 mm in the ra  dial di  -
rec tion, up to 10 mm away from the sur face, and as 0.2
mm along the cy  lin  dri  cal axis, up to 10 mm from the
cen  ter (see fig. 2).
In this sim u la tion by MCNPX codes, all pos si ble 
in  ter  ac  tions of elec  trons with mat  ter were in  cluded
and the doses cal  cu  lated for both elec  trons and pho  -
tons.
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Fig  ure 1. The 
90Y en  ergy spec  trum ac  cord  ing to [17]For scor ing the doses and dose rates, a mesh tally 
(type 3) in MCNPX was used to track the elec trons and 
pho tons and cal cu late their en ergy de po si tion (and the
ab sorbed dose, upon this) for each voxel in the wa ter.
RE SULTS  AND  DIS CUS SION
Depth doses were cal  cu  lated for all voxels over
28 days in or  der to en  sure a full de  cay of the ra  dio  iso  -
tope. These cu mu la tive doses were cal cu lated along the
cy lin dri cal  axis  for  var i ous  ra dial  dis tances  from  the
stent sur  face, as shown in fig. 3. The ab  sorbed dose at
0.1 mm from the sur face var ies from 2400 cGy over the
strut wires to 1230 cGy at the in ter stices. The val ues for
r = 0.5 mm were be  tween 1250 cGy and 650 cGy.
Fig  ure 4 shows the cu  mu  la  tive dose over strut
wires at r = 0.1 mm through  out 28 days. The 90Y stent
de  liv  ers 84% of the whole ab  sorbed dose for 28 days
in the first 7 days that it shows a high dose per cent age.
All  sta tis ti cal  vari ances  for r = 0.1 mm out from the
sur face were less than 2% and for ra dial dis tances up to 
10 mm from the sur  face they were less than 7%.
These dose cal  cu  la  tions show good agree  ment
with the re  sults of [14] at all of the var  i  ous dis  tances
ex  cept for the max  i  mum dose over struts at 0.1 mm
that Carter et al. re  ported as 3500 cGy for 28 days.
This rel  a  tively large dif  fer  ence be  tween the val  ues
may be due to the set  ting of the en  ergy spec  trum for
90Y. We care  fully used a con  tin  u  ous en  ergy spec  trum
of 90Y ranged from zero to 2.28 MeV, based on [17]. 
Fur  ther  more, a Monte Carlo anal  y  sis is used in
this work, whereas the men  tioned au  thors used a dif  -
fer ent,  nu mer i cal  ap proach  [18]  to  sim u late  and  per -
form the do  sim  e  try pro  ce  dure which would cer  tainly
af  fect the par  ti  cle trans  port method and ,thus, the re  -
sult ing  dose  dis tri bu tion.
Fig ure 5 rep re sents the dose rates over 28 days at
r = 0.1 mm and r = 8.5 mm out of the sur face. This plot
in di cates  that  the  90Y stent has a sharp dose gra  di  ent
and, due to high dose rate de  cays, faster than other
com mon ra dio iso topes such as  32P. As shown in fig. 5,
the dose rate value is in  sig  nif  i  cant at the end of 28
days.
In the next step, the fo  cus is on ra  di  a  tion safety
of  the  ra dio ac tive  stent  im plan ta tion  cor re spond ing  to
the ICRP103 re  port.
Con  sid  er  ing the in  crease of the weight  ing tis  sue
fac  tors for some tis  sues like the breasts in ICRP103
[16], there seems to be a need for more pre cise do sim e -
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Fig  ure 2. (a) A sim  ple scheme of the ex  tended cy  lin  dri  cal (grid) ge  om  e  try of the stent and (b) the stent in  side the
car dio vas cu lar sys tem and sur round ing tis sues (wa ter) with voxels in a cy lin dri cal co-or di nate sys tem for dose cal cu la tions
Fig  ure 3. A 2-D cu  mu  la  tive dose dis  tri  bu  tion around a
4 mCi stan  dard 
90Y stent vs. the dis  tance from the
cy  lin  dri  cal axis of the stent for var  i  ous ra  dial dis  tances
from the stent sur  face (1 Ci = 3.7×10
10 Bq)
Fig ure 4. A plot of the max i mum cu mu la tive dose over 28
days of ra di  a  tion treat ment for a stan  dard 
90Y stent with
an ac  tiv  ity of 1.48×10
5 Bqtry  cal cu la tions  be fore  clin i cal  pro ce dures  of  car dio -
vas cu lar  restenosis  us ing  ra dio ac tive  sources  are  ap -
plied.
From the above re  sults, as shown in fig. 5, for the
90Y stent at r = 8.5 mm out from the stent sur face, an ini -
tial dose rate of 1.7×10–5 cGy/s is ob  tained, reach  ing
1.28×10–5 cGy/s, 9.72×10–6 cGy/s, 7.5×10–6 cGy/s,
2.5×10–6 cGy/s, 2.8×10–7 cGy/s, and 1.1×10–8 cGy/s af ter
1, 2, 3, 7, 14, and 28 days, re spec tively. Con se quently, a
cu mu la tive dose and a to tal dose equiv a lent of 23.8 cGy
and 238 mSv, re spec tively, may be de liv ered to such tis -
sues af  ter 28 days (in  deed, if those or  gans just con  trib  -
ute in one voxel row at r  = 8.5 mm along the z-axis, they
may likely over  lap for more than one voxel row!). In
other words, re  gard  ing the weight  ing fac  tor of 0.12 for
breasts [16], the con  tri  bu  tion of the breast tis  sue dose
alone in the ef  fec  tive dose will be about 28.56 mSv.
This value is rel  a  tively high and un  fa  vor  able. The
weight  ing fac  tor for lymph nodes and car  diac tis  sue is
about 0.01, so their con  tri  bu  tion in the ef  fec  tive dose
will be equal to 2.38 mSv. How  ever, these side ef  fects
are as  so  ci  ated with the ac  tiv  ity and de  sign of the stent
and the po  si  tion of the ar  tery. The greater ac  tiv  ity, re  -
sults the higher ab  sorbed dose. The prox  im  ity of the
treated ar  tery to men  tioned or  gans also in  creases the
risk  of  un de sir able  ab sorbed  doses.
Saghamanesh  et al. worked on safety con  cerns
about  car dio vas cu lar  brachytherapy  with  90Sr/90Y seed
sources in [8].
In that re search, they cal cu lated the dose rates for the  
max i mum  dis tances  of  seeds.  For a sin gle seed, they  ob -
tained  an  av er age  dose rate of about 9.683×10–4 cGy/s (or
a dose equiv  a  lent of 9.683×10–3  mSv/s) for a voxel at r =
=.10 mm (that is equiv  a  lent to r = 8.5 mm from the
90Y-stent sur  face) [8]. Con  sid  er  ing all voxels for a train of
8 seeds and an av er age time of 5-15 min utes to be taken for 
the treat  ment, a cu  mu  la  tive (to  tal) dose of about 56-167
cGy (or a to  tal dose equiv  a  lent to 560-1670 mSv) will be
cal  cu  lated. It means that in such a cath  e  ter-based sys  tem,
the con  tri  bu  tion of the breast dose in the ef  fec  tive dose (if
they over  lap in that area) will be about 60-181 mSv. Also,
in  this  method,  the  con  tri  bu  tion  of  the  car  diac  tis  sue
and  lymph  nodes  in the ef  fec  tive dose will be 5.6-16.7
mSv.
It is ev  i  dent that the use of 90Sr/90Y seeds, al  -
though tak  ing less time, may de  liver a high to  tal dose
to the sur  round  ing nor  mal tis  sues and, con  se  quently,
cause more in verse ef fects on the pa tient. How ever, we 
can also see a more uni  form dose pro  file and end  point
dose in a train of seed sources than in a ra  dio  ac  tive
stent (see [8] and fig. 3).
Nev er the less, con sid er ing the cited cal cu la tions, 
it can be con cluded that the to tal dose rate and cu mu la -
tive dose in a 90Y-stent im  plant is much lesser than the
high dose rate (HDR) in a cath e ter-based pro ce dure. In 
other words, de pend ing on the po si tion of the cor o nary 
ar  tery and, also, the ac  tiv  ity of the stent, we should
con  sider a higher pos  si  bil  ity of risk when us  ing 90Y
seed sources.
CON CLU SIONS
A good ra dio ac tive stent should have: (1) a short
half-life for use in per ma nent and low-dose-rate ir ra di -
a  tion, (2) a good high-en  ergy to pen  e  trate the plaque
ar eas but avoid other tis sues, and (3) a high enough ac -
tiv ity to pre  vent restenosis over the en  tire stent and, in
par tic u lar,  at  stent  mar gins.
A Monte Carlo ap  proach was used to cal  cu  late a
3-D dose dis  tri  bu  tion for a stan  dard 90Y stent used in  
intracoronary  ra di a tion  treat ment.  All  sta tis ti cal  vari -
ances at all dis  tances were less than 7%, ver  i  fy  ing the
sim  u  la  tion pro  cess. The re  sults were in good agree  -
ment with a cou  ple of pre  vi  ous works done on the do  -
sim e try  of  a  90Y stent, ex  cept for the max  i  mum cu  mu  -
la  tive dose. Since we used a re  al  is  tic con  tin  u  ous
en  ergy spec  trum and a sta  tis  ti  cal method to trans  port
par  ti  cles rather than a nu  mer  i  cal method to com  pute
doses, it is ex  pected that a more ac cu rate sim  u la  tion is
pro vided.
Be  cause the cor  o  nary ves  sel is in the vi  cin  ity of
sen  si  tive tis  sue such as the breast and lymph nodes,
some of whose tis  sue weight  ing fac  tors have been in  -
creased in the ICRP103's re  port (breast), and since we
may not have an ex act knowl edge of the to tal ab sorbed 
dose in the sur  round  ing tis  sues, we chose the quan  tity
of the “dose equiv  a  lent” to eval  u  ate the dose for nor  -
mal tis  sues. For a cal  cu  lated dis  tant point r = 8.5 mm
out from the stent sur  face, a to  tal dose equiv  a  lent of
about 238 mSv was ob  tained af  ter 28 days. Also, the
val  ues of the dose equiv  a  lent were com  pared with
those of 90Sr/90Y seed sources for a HDR tem  po  rary
intravascular brachytherapy. For the same dis  tance
away from the seeds, the ref er ence [8] achieved a dose
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Fig ure 5. The 28-day dose rate for a 1.48×10
5 Bq stan dard
90Y stent for two near and far dis tances out from the stent
sur  face. The ab  sorbed dose rates show a sharp de  crease
dur  ing 28 days af  ter the im  plantequiv  a  lent of about 1670 mSv. There  fore, de  pend  ing
on the po  si  tion of the cor  o  nary ar  tery rel  a  tive to the
breast or lymph nodes and the ac  tiv  ity of the stent, we
can con clude that pos si ble risks in crease when us ing a
90Sr/90Y seed source, more so than with the im  plan  ta  -
tion of a 90Y ra dio ac tive stent. How ever, it is also ob vi -
ous that stents with more ac tiv ity could pose ei ther the
same as risks as 90Sr/90Y seeds or even greater ones to
nor  mal tis  sue. Thus, in ad  di  tion to other med  i  cal ad  -
van tages and dis ad van tages of us ing stents, a thor ough 
re view of the pos si bil ity of side ef fects of 90Y ra dio ac -
tive stents with dif  fer  ent de  signs and ac  tiv  i  ties is
needed be  fore em  bark  ing on the treat  ment pro  ce  dure.
It may be rea  son  able to con  sider us  ing 90Sr/90Y seed
sources with lower ac  tiv  ity for choos  ing a proper and
safe method of re  duc  ing restenosis.
AU THOR  CON TRI BU TIONS
The  de sign  and  the o ret i cal  anal y sis  of  this  re -
search work was car  ried out by A. Karimian. Monte
Carlo  sim u la tion  and  the  manu script,  in clud ing  fig -
ures and text, were pre  pared and writ  ten by A.
Karimian and S. Saghamanesh.
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Alireza KARIMIAN, Somajeh SAGHAMANE[
DOZIMETRIJSKA  PROCENA  IMPLANTACIJE  ITRIJUMSKIH
STENTOVA  U  INTRAKORONARNOM  RADIJACIONIM  LE^EWU
Jonizuju}e ~estice koriste se za le~ewe ateroskleroze. Unutra{we ozra~ivawe obi~no
se izvodi razli~itim metodama (postupcima zasnovanim na kateteru, radioaktivnim stentovima,
ili balonima), kako bi se umawila verovatno}a restenoze. Zahvaquju}i svojim karakteristikama,
90Y je pogodan radionuklid za intravaskularnu brahiterapiju. Me|utim, po{to se u blizini srca
nalaze neka kriti~na tkiva, kao {to su dojke i limfni ~vorovi, neophodno je uraditi
dozimetrijske prora~une u okolini arterije kako bi se opravdala metoda le~ewa. U ovom radu,
programskim paketom MCNPX, dobijena je 3-D raspodela doze u okolini sr~ane kese i okolnih
tkiva za standardni 90Y stent. Rezultati su upore|eni sa drugim metodama spre~avawa restenoze
kori{}ewem stentova prekrivenih 90Y. Prora~uni predstavqaju kumulativnu dozu za pe riod od 28
dana u opsegu od 1230 cGy do 2400 cGy na udaqenosti 0.1 mm od povr{ine stenta, dok je na 8.5 mm od
stenta kumulativna doza iznosila 23.8 cGy. Za pomenuto okolno tkivo, prema posledwim izmenama
u ICRP preporukama, proceweni su dozni ekvivalent i efektivna doza na rastojawu od 8.5 mm.
Dozni ekvivalent za ove organe, izra~unat za pe  riod le~ewa, upore|en je sa objavqenim
rezultatima za 90Sr/90Y izvore kako bi se procenile posledice zra~ewa kod ove dve metode
radioterapije. Ustanovqeno je da u zavisnosti od karakteristika stenta, 90Y stent implanti mogu
pove}ati ne`eqene efekte za pacijenta, ali u mnogo mawem obimu nego druge metode.
Kqu~ne re~i: intravaskularna brahiterapija, restenoza, Monte Karlo simulacija, 90Y